Show
Sort by
-
- Journal Article
- A1
- open access
Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion protein
-
New antibody-based prevention and treatment options for influenza
-
- Journal Article
- A1
- open access
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1
-
- Journal Article
- A1
- open access
The natural compound silvestrol inhibits hepatitis E virus (HEV) replication in vitro and in vivo
-
Passively transferred M2e-specific monoclonal antibody reduces influenza A virus transmission in mice
-
Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy
-
Bispecific T cell engaging antibody constructs targeting a universally conserved part of the viral M2 ectodomain cure and prevent influenza A virus infection
-
Transmission of hepatitis E virus infection to human-liver chimeric FRG mice using patient plasma
-
A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo
-
Pentagalloylglucose, a highly bioavailable polyphenolic compound present in Cortex moutan, efficiently blocks hepatitis C virus entry
-
Multidrug-resistant cytomegalovirus infection in a pediatric stem cell transplantation patient
-
- Journal Article
- A1
- open access
Immuno-modulating properties of saliphenylhalamide, SNS-032, obatoclax, and gemcitabine
-
Evaluation of the antiviral activity of (1'S,2'R)-9-[[1',2'-bis(hydroxymethyl)cycloprop-1'-yl]methyl]guanine (A-5021) against equine herpesvirus type 1 in cell monolayers and equine nasal mucosal explants
-
Nanobodies®: new ammunition to battle viruses
-
Synergistic in vitro anti-HIV type 1 activity of tenofovir with carbohydrate-binding agents (CBAs)
-
The human liver-uPA-SCID mouse: A model for the evaluation of antiviral compounds against HBV and HCV
-
A dual chamber model of female cervical mucosa for the study of HIV transmission and for the evaluation of candidate HIV microbicides
-
Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle
-
Carbohydrate-binding agents (CBAs) selectively target the glycoproteins of the HCV and HIV envelope to prevent viral entry
-
Inhibition of replication of primary HIV-1 isolates in huPBL-NOD/Scid mice by antibodies from HIV-1 infected patients
-
Carbohydrate-binding agents (CBAs) potently inhibit HIV infection in human primary monocytes/macrophages and efficiently prevent viral capture and subsequent transmission to CD+4 T lymphocytes
-
Antiviral activity of carbohydrate-binding agents against Nidovirales in cell culture
-
- Journal Article
- A1
- open access
The nucleocapsid of the hepatitis B virus: a remarkable immunogenic structure